Related Experiment Video
Updated: May 7, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
Cardiac toxicity of some echinocandin antifungals
Kayla R Stover1, Jerry M Farley, Patrick B Kyle
1University of Mississippi, Pharmacy Practice , 2500 North State Street, Jackson, MS 39216 , USA kstover@umc.edu.
Background:
Unexplained cardiovascular decompensation has been observed during central venous administration of some echinocandins.
Objective:
The purpose of this study was to assess cardiac toxicity associated with the echinocandins.
Methods:
Isolated rat hearts (Langendorff model) were perfused with anidulafungin (ANID), caspofungin (CASP), or micafungin (MICA) at exposures of 1, 4, and 10 times therapeutic concentrations. Changes in left ventricular contractility with experimental exposure were compared to control, and histologic and transmission electron microscopy (TEM) examinations of tissue were performed.
Results:
Mean concentrations of ANID (10 - 80 µg/ml) and CASP (6 - 48 µg/ml) were associated with significant decreases in contractility (-77.1 ± 9.4% and -40.6 ± 15.6%, respectively; p < 0.05). MICA was associated with an increase in contractility (13.6 ± 2.8%, p = NS). On TEM, samples exposed to ANID and CASP had enlarged mitochondria and disintegrating myofibrils. Samples exposed to MICA showed some enlarged mitochondria.
Conclusion:
Mean concentrations of ANID and CASP were associated with statistically significant decreases in left ventricular contractility at concentrations that may be achievable in humans after peripheral administration, while MICA caused no change. TEM studies suggest this may be a result of mitochondrial damage. Caution may be warranted with central administration of these agents to patients with preexisting cardiac dysfunction.
Related Concept Videos
Antifungal Agents
Drug toxicity: Drug–Drug Interaction
Heart Failure Drugs: Inotropic Agents
Cardiac Catheterization I: Pre-Procedure Overview
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Toxicity: Dose-Dependent Reactions
